Related Experiment Video

Updated: Apr 30, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.1K

BASI, a potent small molecular inhibitor, inhibits glioblastoma progression by targeting microRNA-mediated β-catenin

Zhen-Dong Shi1, Xiao-Min Qian, Jun-Xia Zhang

  • 1Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China; Key Laboratory of Post-Trauma Neuro-Repair and Regeneration in the Central Nervous System, Ministry of Education Tianjin Key Laboratory of Injuries, Variations and Regeneration of the Nervous System, Tianjin, China.

CNS Neuroscience & Therapeutics
|May 10, 2014
PubMed
Abstract

Insights

A novel compound, BASI, effectively inhibits beta-catenin (β-catenin) signaling in glioblastoma. This natural molecule suppressed tumor growth and invasion, offering a promising new therapeutic strategy for brain cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Nuclear localization of beta-catenin (β-catenin) is implicated in various cancers, driving tumor progression and metastasis.
  • Targeting β-catenin is a key therapeutic strategy for numerous cancer types.

Purpose of the Study:

  • To identify and evaluate a natural small molecule inhibitor of β-catenin signaling.
  • To assess the therapeutic efficacy of BASI in glioblastoma models.

Main Methods:

  • In vitro studies on glioblastoma cells.
  • In vivo evaluation using orthotopic mouse models of glioma.
  • Analysis of microRNA expression changes and their role in β-catenin regulation.

Main Results:

  • BASI significantly inhibited glioblastoma cell proliferation and invasion while inducing apoptosis.
  • Orthotopic tumor growth in vivo was markedly reduced by BASI treatment.
  • BASI modulated microRNA expression, leading to posttranscriptional silencing of β-catenin via VHL-mediated degradation.

Conclusions:

  • BASI demonstrates preclinical efficacy as a novel β-catenin inhibitor for glioblastoma.
  • The compound's mechanism involves microRNA-mediated regulation of β-catenin.
  • BASI holds significant potential for advancing glioblastoma treatment strategies.
Keywords:
BASIGlioblastomaInhibitormicroRNAβ-Catenin

More Related Videos

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion09:23

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Published on: October 20, 2016

13.6K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K